Metastatic duodenal GIST: role of surgery combined with imatinib mesylate

doi:10.1186/1477-7800-4-9

International Seminars in Surgical Oncology

Volume 4

Viewing options:

Abstract
Full text
PDF (1.3MB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Mohiuddin K
Nizami S
Munir A
Memon B
Memon MA

on PubMed

Mohiuddin K
Nizami S
Munir A
Memon B
Memon MA
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Case report

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate

Kamran Mohiuddin¹^,2 , Saira Nizami¹^,2 , Asma Munir¹ , Breda Memon² and Muhammed A Memon²

¹Department of Surgery, Aga Khan University Hospital, Karachi, Pakistan

²Department of Surgery, Whiston Hospital, Warrington Road, Prescot, Merseyside, UK

author email corresponding author email

International Seminars in Surgical Oncology 2007, 4:9doi:10.1186/1477-7800-4-9


Published:	29 March 2007

Abstract

Background

The best possible treatment of metastatic high grade large duodenal GIST is controversial. Surgery (with or without segmental organ resection) remains the principal treatment for primary and recurrent GIST. However, patients with advanced duodenal GIST have a high risk of early tumour recurrence and short life expectancy.

Method

We present a case of a young man treated with a combined modality of surgery and imatinib for an advanced duodenal GIST.

Results

He remains asymptomatic and disease free 42 months following this combined approach.

Conclusion

Treatment with imatinib has dramatically improved the outlook for patients with advanced, unresectable and/or metastatic disease.